Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large medicaid population

Journal of Clinical Psychiatry

Volumn 72, Issue 8, 2011, Pages 1079-1085

  Boaz, Timothy L ^a   Constantine, Robert J ^a   Robst, John ^a   Becker, Marion A ^a   Howe, Andrew M ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HOSPITAL CARE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAID; POLYPHARMACY; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHOOL CHILD; SEX DIFFERENCE; SUBSTANCE ABUSE; TREATMENT WITHDRAWAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; FLORIDA; GUIDELINE ADHERENCE; HUMANS; INJECTIONS, INTRAMUSCULAR; INSURANCE CLAIM REVIEW; MALE; MEDICAID; MENTAL DISORDERS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; UNITED STATES; YOUNG ADULT;

EID: 80052430186     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05348yel     Document Type: Article

References (33)

1. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23(4):637-651. PubMed (Pubitemid 27485972)
2. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49(2):196-201. PubMed (Pubitemid 28071427)
3. Velligan DI, Lam F, Ereshefsky L, et al. Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv. 2003;54(5):665-667. doi:10.176/api.ps.54.5.65 PubMed (Pubitemid 36752956)
4. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30(2):255-264. PubMed (Pubitemid 38828533)
5. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40(8):630-639. doi:10.1097/05650-202080-02 PubMed
6. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52(6):805-811. doi:10.176/api.ps.52.6.805 PubMed (Pubitemid 32577440)
7. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21(3):419-429. PubMed
8. Babiker IE. Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. J Clin Psychiatry. 1987;48(3):94-97. PubMed (Pubitemid 17047796)
9. Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs. 1994;47(5):741-773. doi:10.2165/03495-1947050-04 PubMed (Pubitemid 24151095)
10. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry. 1992;53(12):426-433. PubMed (Pubitemid 23018085)
11. Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull. 2003;29(3):531-540. PubMed (Pubitemid 37339387)
12. Marder SR. Overview of partial compliance. J Clin Psychiatry. 2003; 64(suppl 16):3-9. PubMed (Pubitemid 37523321)
13. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry. 2003;64(suppl 16):34-40. PubMed (Pubitemid 37523326)
14. Tandon R, Belmaker RH, Gattaz WF, et al Section of Pharmacopsychiatry, World Psychiatric Association. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008;100(1-3):20-38. doi:10.1016/j.schres.207.1.03 PubMed
15. Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346(1):16-22. doi:10.1056/NEJMoa02028 PubMed (Pubitemid 34438915)
16. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology. 2003; 28(suppl 1):9-26. doi:10.1016/S0306-4530(02)010-5 PubMed (Pubitemid 36015659)
17. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003;64(10):1250-1257. PubMed
18. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111-117. doi:10.1016/j.euroneuro.204.07.03 PubMed (Pubitemid 39574406)
19. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125-1132. doi:10.176/api.ajp.160.6. 125 PubMed (Pubitemid 41070972)
20. Rossi A, Bernareggi MM, Giustra MG. Clinical maintenance response with risperidone long-acting injectable (RLAI) in subjects with schizophrenia or schizoaffective disorder: a 52 weeks Italian study. Eur Psychiatry. 2008;23(suppl 2):S167-S168.
21. Cassola RS, Cabra OS, Menguiano CM. Descriptive study about longacting injectable risperidone (RLAI) in outpatients. Eur Psychiatry. 2007;22(1):S165-S166.
22. Diels J, Olivares JM, Rodriguez-Morales A, et al. Comparing risperidone long-acting injection (RLAI) with oral antipsychotics in Spanish patients with schizophrenia using propensity scoring. Eur Psychiatry. 2007;22(1):S110-S111. doi:10.1016/j.eurpsy.207.01.351
23. Schmauss M, Sacchetti E, Kahn JP, et al. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol. 2007;22(2):85-92. doi:10.1097/YIC.0b013e328019db PubMed
24. Consta R. [package insert]. Titusville, NJ: Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2008.
25. Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R D. 2005;6(3):129-137. doi:10.2165/0126839-20506030-01 PubMed (Pubitemid 40994250)
26. Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull. 2007;33(6):1379-1387. doi:10.1093/schbul/sbm03 PubMed (Pubitemid 350022772)
27. Constantine RJ, Andel R, Tandon R. Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program. Community Ment Health J. Jan 23. 2010; [Epub ahead of print]. doi:10.107/s10597-09-928-2 PubMed
28. Fayek M, Flowers C, Signorelli D, et al. Psychopharmacology: underuse of evidence-based treatments in psychiatry. Psychiatr Serv. 2003; 54(11):1453-1454, 1456. doi:10.176/api.ps.54.1.1453 PubMed
29. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand. 2007;116(1):36-46. doi:10.1/j.160-047.206.0980.x PubMed
30. Taylor DM, Young CL, Mace S, et al. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry. 2004;65(8):1076-1083. doi:10.408/JCP.v65n0808 PubMed
31. Taylor D. Risperidone long-acting injection in practice-acting injection in practiceMore questions than answers? Acta Psychiatr Scand. 2006;114(1):1-2. doi:10.1/j.160-047.206.0810.x PubMed (Pubitemid 43885478)
32. Nesvåg R, Hendset M, Refsum H, et al. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand. 2006;114(1):21-26. doi:10.1/j.160-047.206.0840.x PubMed (Pubitemid 43885481)
33. Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005;8(1):27-36. doi:10.1017/S14614570404924 PubMed (Pubitemid 40388811)